Artificial Pancreas Device System Market Summary

• The Artificial Pancreas Device Systems market is estimated at USD 785 million in 2025 and is projected to reach USD 4.05 billion by 2034. Growth is anchored in the rising global prevalence of type 1 and insulin-dependent type 2 diabetes, the rapid shift from manual and threshold-suspend insulin therapy toward hybrid and fully closed-loop automated insulin delivery, and expanding regulatory approvals and reimbursement support.
• The global Artificial Pancreas Device Systems market is growing at a CAGR of 20.0% during the forecast period from 2026 to 2034.
• By device type, the Control-to-Target Systems segment dominated the Artificial Pancreas Device Systems market with a 54% share in 2025.
• By treatment type, the Insulin Only segment dominated the Artificial Pancreas Device Systems market with an 87% share in 2025.
• By end-user, the Homecare Settings segment dominated the Artificial Pancreas Device Systems market with a 47% share in 2025.
• North America dominated the global Artificial Pancreas Device Systems market revenue with a 42% share in 2025, representing the highest regional market share globally.

An artificial pancreas device system (APDS) is a closed-loop or automated insulin delivery (AID) system that manages blood glucose levels by automatically regulating insulin dosing. It comprises a continuous glucose monitor (CGM), a subcutaneous insulin infusion pump, and a controller that links the monitor with the pump through a dosing algorithm. The algorithm continuously evaluates real-time glucose readings and calculates the appropriate insulin dose and delivery timing, minimizing the risk of hyperglycemia and hypoglycemia for people living with diabetes, most commonly type 1 diabetes, with growing adoption among insulin-dependent type 2 diabetes patients. The market is organized by device type across threshold suspend device systems, control-to-range systems, and control-to-target systems; by treatment type across bi-hormonal and insulin-only systems; and by end-user across hospitals, medical centers, homecare settings, and others. Driven by the rising global diabetes burden, rapid technological convergence of CGM and pump platforms, growing patch-pump competitive intensity, and expanding regulatory clearances and label expansions, artificial pancreas device systems are becoming the standard of care in advanced diabetes management.

Artificial Pancreas Device Systems Market Key Growth Drivers

• The rapid clinical and commercial expansion of hybrid and fully closed-loop automated insulin delivery systems is driving demand, with the International Diabetes Federation estimating more than 537 million adults living with diabetes in 2021, projected to reach 643 million by 2030 and 783 million by 2045.
• Regulatory label expansions are broadening the eligible patient pool, including the 2025 FDA approval of Insulet's Omnipod 5 for use in people with type 2 diabetes.
• Intensifying competition in the patch-pump category is accelerating innovation, exemplified by Beta Bionics' FDA clearance of its Mint tubeless insulin pump in September 2026 and Tandem Diabetes Care's continued expansion of its Tandem Mobi platform.
• Smartphone-controlled, software-first automated insulin dosing is gaining traction, illustrated by Diabeloop's FDA clearance of DBLG2 and its commercial rollout with the ViCentra Kaleido patch pump and Dexcom G7 sensor across Europe.
• Rising healthcare investment and growing homecare adoption are expanding reimbursement pathways and out-of-hospital access to closed-loop therapy across developed and emerging markets.
• Strong investor interest in diabetes technology is accelerating capacity build-out and product pipelines, reflected in Beta Bionics' USD 204 million initial public offering in January 2025 and continued strategic collaborations such as Ypsomed's partnership with CamDiab on the CamAPS FX dosing algorithm.
• The convergence of theranostic-grade CGM accuracy, adaptive dosing algorithms, and miniaturized pump hardware is expected to sustain strong double-digit growth in the market through 2034.

Key Companies in Artificial Pancreas Device Systems Market

The competitive landscape is led by the following active manufacturers:

• Medtronic
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Beta Bionics, Inc.
• BIGFOOT BIOMEDICAL, INC.
• CamDiab Ltd.
• Diabeloop SA
• Ypsomed
• INREDA® DIABETIC B.V.
• Nikkiso Co., Ltd.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Artificial Pancreas Device Systems Market Size

The following snapshot summarizes the principal report metrics for the Artificial Pancreas Device Systems market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Artificial Pancreas Device Systems Market

Market Drivers

Rising Global Prevalence of Diabetes

The single most powerful driver of the Artificial Pancreas Device Systems market is the sheer scale and continued rise of the global diabetes population. The International Diabetes Federation estimated that more than 537 million adults aged 20 to 79 were living with diabetes in 2021, a figure projected to climb to 643 million by 2030 and 783 million by 2045, with low- and middle-income countries in Asia, Africa, and Latin America disproportionately affected. Within this population, people with type 1 diabetes and insulin-intensive type 2 diabetes require constant, precise glycemic management, a burden that closed-loop systems are specifically designed to relieve. As diagnosis rates improve and awareness of automated insulin delivery grows, the addressable patient base for artificial pancreas device systems expands directly, anchoring market growth through 2034. 

Rapid Technology Shift Toward Hybrid and Fully Closed-Loop Systems

A structural shift from manual insulin dosing and first-generation threshold-suspend pumps toward hybrid and, increasingly, fully closed-loop control-to-target systems is reshaping the competitive landscape. Systems such as Medtronic's MiniMed 780G, Tandem's Control-IQ+ platform, and Beta Bionics' iLet Bionic Pancreas automatically adjust basal and correction insulin delivery based on real-time CGM data, reducing user burden and improving time-in-range outcomes. As clinical evidence accumulates and patients and clinicians gain confidence in algorithm-driven dosing, adoption is migrating decisively toward the most automated device categories, which is expanding both average selling prices and recurring consumable revenue for manufacturers.

Expanding Regulatory Approvals and Label Expansions

A growing wave of regulatory clearances and label expansions is broadening the eligible patient population and commercial opportunity. In 2025, the FDA approved Insulet's Omnipod 5 for use in people with type 2 diabetes, opening a substantially larger addressable market beyond the traditional type 1 diabetes base. Tandem received FDA clearance for its Mobi system for use with Android smartphones in November 2025, and Diabeloop secured FDA clearance for its DBLG2 smartphone-based algorithm in 2025 alongside CE mark (MDR) approval in Europe. Each approval and label expansion creates durable, recurring demand for compliant manufacturing, software validation, and reliable device supply.

Intensifying Patch-Pump Competition Accelerating Innovation

Competitive intensity in the tubeless patch-pump category is accelerating product development across the industry. Beta Bionics received FDA clearance for its Mint tubeless insulin pump in September 2026 and plans a first-quarter 2027 commercial launch through the pharmacy channel, while Medtronic is developing its own patch pump alongside the smaller, phone-controlled MiniMed 8-series tubed pump, targeted for FDA submission by the close of its 2026 fiscal year. Tandem is likewise advancing multiple patch-pump form factors. This wave of new entrants and next-generation form factors is expanding consumer choice, intensifying price and feature competition, and widening the overall addressable market for automated insulin delivery hardware.

Growth of Homecare-Based, Smartphone-Controlled Therapy

The shift of chronic disease management out of clinical settings and into the home is a durable growth vector for the market. Homecare settings already account for the largest share of end-user demand, supported by smartphone-controlled dosing platforms such as Diabeloop's DBLG2 and DBLG1 with the Dana-i pump, which launched in Germany in September 2025 in partnership with SOOIL Development, Mediq, and Dexcom. As algorithm developers increasingly decouple dosing software from proprietary hardware, and as pump and CGM ecosystems become more interoperable, patients are gaining greater flexibility to manage therapy independently at home, reinforcing sustained volume growth in the homecare segment.

Strong Investor and Strategic Partnership Activity

Surging investor interest and strategic collaboration are accelerating capacity build-out and pipeline development across the sector. Beta Bionics raised USD 204 million in its January 2025 initial public offering, underscoring capital-market confidence in automated insulin delivery. Strategic technology partnerships, including Ypsomed's collaboration with CamDiab to integrate the CamAPS FX dosing algorithm with the MyLife YpsoPump, and Diabeloop's development agreements with ViCentra, Terumo, SOOIL Development, and Roche Diabetes Care, are extending the reach of proprietary algorithms across multiple hardware platforms. This capital and partnership activity is expanding manufacturing capacity, validating the sector's long-term growth trajectory, and channeling sustained demand toward providers with proven algorithms and regulatory track records.

Convergence of CGM Accuracy, AI-Driven Algorithms, and Miniaturized Hardware

Continuous improvement in continuous glucose monitor accuracy, combined with increasingly adaptive, machine-learning-informed dosing algorithms and progressively miniaturized pump hardware, is expanding the clinical and commercial appeal of artificial pancreas device systems. Fully closed-loop systems that eliminate the need for manual meal announcements are advancing through clinical development, and bi-hormonal systems that pair insulin with glucagon, such as the platform developed by Inreda Diabetic, are demonstrating the potential for tighter glycemic control across a broader range of patients. This technology convergence is expected to sustain strong double-digit growth in the market through 2034.

Market Restraints

Despite strong momentum, the Artificial Pancreas Device Systems market faces material constraints. High device and consumable costs, combined with uneven insurance coverage and reimbursement policies across geographies, restrict access for lower-income patients and in emerging markets. The technical complexity of closed-loop algorithms, sensor calibration requirements, and interoperability challenges between CGMs, pumps, and dosing software can create usability barriers, particularly for elderly patients and first-time users. Regulatory pathways for fully closed-loop and bi-hormonal systems remain more demanding than for earlier-generation devices, lengthening time to market and raising development costs, while device recalls and post-market safety reporting requirements, such as FDA scrutiny of unreported complaints, add compliance burden. A shortage of trained endocrinology and diabetes-education staff constrains onboarding and ongoing patient support, and the crowded, rapidly evolving competitive field increases the risk of technology obsolescence for manufacturers with longer development cycles. Together, these cost, complexity, regulatory, workforce, and competitive barriers temper the pace of growth, even as the underlying drivers of rising diabetes prevalence, technology adoption, and homecare migration remain firmly intact.

Artificial Pancreas Device Systems Market Segment Analysis

The Artificial Pancreas Device Systems Market by device type (threshold suspend device systems, control-to-range systems, control-to-target systems), treatment type (bi-hormonal, insulin only), end-user (hospitals, medical centers, homecare settings, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Device Type

Dominant Subsegment: Control-to-Target Systems. 

The control-to-target systems segment accounted for 54% of the Artificial Pancreas Device Systems market in 2025. Control-to-target systems, commonly marketed as hybrid or advanced hybrid closed-loop platforms, including the Medtronic MiniMed 780G, Tandem Control-IQ+, and Beta Bionics iLet Bionic Pancreas, automatically adjust basal insulin delivery toward a specific target glucose value and deliver automated correction doses, providing the highest degree of automation currently available commercially. Their superior glycemic outcomes, growing base of published clinical evidence, and continuous software improvements delivered through connected mobile applications have driven rapid replacement of earlier-generation threshold-suspend devices, which merely stop insulin delivery to prevent hypoglycemia. Control-to-range systems, which moderate insulin delivery within a broader target band rather than to a single set point, occupy an intermediate position and continue to see use, particularly in interoperable and legacy-integrated systems. While control-to-range systems retain a meaningful installed base, the superior automation, growing device approvals, and strong clinical outcomes of control-to-target platforms secure their leadership across the forecast period.

By Treatment Type

Dominant Subsegment: Insulin Only. 

The insulin-only segment accounted for 87% of the Artificial Pancreas Device Systems market in 2025. Insulin-only systems are the leading treatment type because nearly all commercially approved automated insulin delivery devices, including those from Medtronic, Insulet, Tandem, and Beta Bionics, deliver insulin alone, supported by a mature regulatory pathway, well-established insulin pharmacokinetics, and broad payer familiarity. Bi-hormonal systems, which pair insulin with glucagon to both lower and raise glucose levels automatically, such as the platform developed by Inreda Diabetic, offer the theoretical advantage of tighter glycemic control and reduced hypoglycemia risk, but face a more complex regulatory pathway, the added cost and logistics of stable glucagon formulations, and a smaller base of approved commercial products. Bi-hormonal systems are expected to grow rapidly as glucagon stability and formulation challenges are resolved and clinical evidence accumulates, but the scale, regulatory maturity, and manufacturing simplicity of insulin-only systems secure their leadership across the forecast period.

By End-User

Dominant Subsegment: Homecare Settings. 

The homecare settings segment accounted for 47% of the Artificial Pancreas Device Systems market in 2025. Homecare settings lead end-user demand because artificial pancreas device systems are specifically designed for continuous, day-to-day self-management outside of clinical facilities, and the growing sophistication of smartphone-controlled dosing platforms, exemplified by Diabeloop's DBLG1 and DBLG2 systems, has made independent home use increasingly accessible. Remote patient-monitoring capabilities, direct-to-patient distribution through pharmacy and mail-order channels, and expanding telehealth-supported titration further reinforce homecare adoption. Hospitals and medical centers remain important for initial device fitting, training, and management of complex or newly diagnosed cases, and the 'others' category, spanning long-term care and school or workplace settings, contributes a smaller share. Nonetheless, the sheer frequency and duration of at-home glycemic management secure the homecare segment's leadership across the forecast period.

Artificial Pancreas Device Systems Market Region Analysis

Dominant Region: North America

North America accounted for 42% of the global Artificial Pancreas Device Systems market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature diabetes-technology ecosystem, high rates of CGM and insulin pump adoption, strong private and public insurance coverage, and the presence of leading manufacturers headquartered in the United States, including Medtronic, Insulet, Tandem Diabetes Care, and Beta Bionics. The United States hosts the largest concentration of automated insulin delivery users globally, supported by clear FDA regulatory pathways, an established base of endocrinology specialists, and rapid uptake of newly approved systems such as Omnipod 5 in the type 2 diabetes population. Continued new product launches, including Tandem Mobi's Android compatibility and Beta Bionics' Mint patch pump, alongside expanding pediatric and homecare adoption, anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Artificial Pancreas Device Systems market. The region's elevated CAGR is driven by a rapidly rising diabetes population, expanding healthcare infrastructure, and growing government investment in chronic disease management across China, Japan, India, South Korea, and Australia. Japan is a hub for diabetes-technology innovation and hosts manufacturers such as Nikkiso; China is expanding CGM and insulin pump manufacturing and distribution capacity, India is emerging as a large underpenetrated market with rising middle-class access to advanced diabetes care, and Australia benefits from strong public reimbursement of hybrid closed-loop systems. Rising disease awareness, expanding local manufacturing partnerships, and growing clinical-trial activity position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 42% of the global Artificial Pancreas Device Systems market revenue in 2025. The United States dominates on the strength of its diabetes-technology manufacturing base, favorable reimbursement environment, and rapid adoption of newly approved systems, while ongoing new product launches from Medtronic, Insulet, Tandem, and Beta Bionics reinforce its leadership.

Europe

Europe is a large and technologically advanced regional market, supported by established CE mark and Medical Device Regulation (MDR) frameworks, strong national reimbursement of hybrid closed-loop systems in markets including the United Kingdom, Germany, France, and the Netherlands, and a concentration of algorithm and device innovators such as Diabeloop, CamDiab, Ypsomed, and Inreda Diabetic. Growing cross-border partnerships, such as Diabeloop's rollout of DBLG1 and DBLG2 across France, Germany, and the Netherlands, reinforce the region's leadership in software-driven automated insulin delivery.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising diabetes incidence, expanding healthcare infrastructure, and growing government investment across China, Japan, India, South Korea, and Australia. Japan's presence in diabetes-device manufacturing through companies such as Nikkiso, China's expanding local production, and rising clinical-trial activity are accelerating regional adoption of automated insulin delivery systems.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Rising diabetes prevalence, gradually improving healthcare infrastructure, and growing efforts to expand insurance coverage and access to advanced diabetes technologies are broadening the addressable market, while international distribution partnerships support gradual market entry by established manufacturers.

Artificial Pancreas Device Systems Market Competitive Landscape

The Artificial Pancreas Device Systems market is classified as Fragmented, with Increasing Concentration among Top-Tier Players. Established medical device leaders with broad commercial infrastructure and regulatory track records, including Medtronic, Insulet Corporation, and Tandem Diabetes Care, anchor the top tier and account for the large majority of installed devices, while specialized and fast-scaling providers such as Beta Bionics, Bigfoot Biomedical, CamDiab, Diabeloop, Ypsomed, Inreda Diabetic, and Nikkiso compete through differentiated algorithms, novel form factors, bi-hormonal technology, and strategic hardware partnerships, increasing competitive intensity across device type and geography.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Fragmented overall, with three established leaders (Medtronic, Insulet, Tandem) controlling the majority share and a fast-growing field of specialized challengers.
• Leading players: Medtronic, Insulet Corporation, and Tandem Diabetes Care, Inc. anchor the top tier through installed base, manufacturing scale, and payer relationships.
• Geographic reach: Leaders operate global commercial networks spanning North America, Europe, and expanding into Asia-Pacific; algorithm developers such as Diabeloop extend reach through multi-hardware partnerships across several European countries.
• Product portfolio strength: Top players offer integrated CGM-pump-algorithm ecosystems spanning tubed and tubeless pumps, smartphone control, and interoperable, alternate-controller-enabled platforms.
• Technology differentiation: Advanced hybrid closed-loop algorithms, adaptive dosing, patch-pump miniaturization, and bi-hormonal insulin-glucagon control are decisive competitive advantages.
• Strategic partnerships: Tie-ups between hardware and algorithm developers, such as Ypsomed's partnership with CamDiab and Diabeloop's agreements with ViCentra, Terumo, SOOIL Development, and Roche Diabetes Care, extend commercial reach.
• Capital markets activity: Active fundraising and public-market entry, including Beta Bionics' USD 204 million initial public offering in January 2025, reflect strong investor conviction in the category.
• Manufacturing capabilities: Miniaturized pump hardware, high-volume disposable patch-pump production, and software validation infrastructure are key competitive moats.
• Innovation focus: Fully closed-loop control for type 1 and type 2 diabetes, smartphone-native dosing, bi-hormonal glucose control, and AI-driven adaptive algorithms.

Artificial Pancreas Device Systems Market Recent Developmental Activities

In September 2026, Beta Bionics, Inc. received FDA clearance for its Mint tubeless insulin patch pump, featuring a three-day wear time and a 200-unit insulin reservoir, with a full U.S. launch planned for the first quarter of 2027 through the pharmacy channel.

In June 2026, Insulet Corporation previewed Omnipod 6, its next-generation hybrid closed-loop system featuring an improved adaptive algorithm, at the American Diabetes Association's Scientific Sessions, alongside initiation of the EVOLVE FDA investigational device exemption study for fully closed-loop technology in type 2 diabetes.

In 2026, Medtronic advanced development of its next-generation MiniMed 8-series pump, a screen-free, phone-controlled tubed pump roughly half the size of the current MiniMed 780G, alongside a new insulin patch pump, with FDA submission targeted by the close of its 2026 fiscal year.

In November 2025, Tandem Diabetes Care, Inc. received FDA clearance for its Tandem Mobi insulin delivery system, powered by Control-IQ+ technology, for use with Android smartphones, and separately received CE Mark for Tandem Mobi with Control-IQ+ in Europe.

In 2025, Insulet Corporation received FDA approval for its Omnipod 5 automated insulin delivery system for use in individuals with type 2 diabetes.

In September 2025, Diabeloop SA launched its DBLG1 automated insulin delivery system integrated with the SOOIL Development Dana-i pump in Germany, in partnership with Mediq and Dexcom.

Artificial Pancreas Device Systems Market Segmentation

Artificial Pancreas Device Systems Market by Device Type

• Threshold Suspend Device Systems
• Control-to-Range Systems
• Control-to-Target Systems

Artificial Pancreas Device Systems Market by Treatment Type

• Bi-hormonal
• Insulin Only

Artificial Pancreas Device Systems Market by End-Users

• Hospitals
• Medical Centers
• Homecare Settings
• Others

Artificial Pancreas Device Systems Market by Geography

• North America Artificial Pancreas Device Systems Market

• United States Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Canada Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Mexico Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Europe Artificial Pancreas Device Systems Market
• Germany Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• United Kingdom Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• France Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Italy Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Spain Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Rest of Europe Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Asia-Pacific Artificial Pancreas Device Systems Market
• China Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Japan Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• India Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Australia Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• South Korea Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Rest of the World (RoW) Artificial Pancreas Device Systems Market
• Middle East Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• Africa Artificial Pancreas Device Systems Market Size in USD million (2023-2034)
• South America Artificial Pancreas Device Systems Market Size in USD million (2023-2034)

Artificial Pancreas Device Systems Market Recent Industry Trends and Milestones (2023-2026)

Artificial Pancreas Device Systems Market Startup Funding and Investment Trends

Investment in the Artificial Pancreas Device Systems ecosystem has concentrated on patch-pump miniaturization, smartphone-native dosing algorithms, and bi-hormonal closed-loop technology. The following companies illustrate recent funding and investment activity and technology focus.

Capital is flowing toward providers that combine differentiated algorithms with flexible hardware partnerships. Beta Bionics' USD 204 million initial public offering in January 2025 underscores strong investor conviction in automated insulin delivery, while Diabeloop's continued fundraising and multi-hardware partnerships with ViCentra, Terumo, SOOIL Development, and Roche Diabetes Care illustrate the growing value of hardware-agnostic dosing software. Emerging and specialized providers such as Bigfoot Biomedical, CamDiab, and Inreda Diabetic are advancing interoperable and bi-hormonal technology, while established leaders Medtronic, Insulet, and Tandem continue to reinvest in next-generation pump platforms. Collectively, these investments signal conviction that algorithm differentiation, patch-pump innovation, and homecare accessibility will define the next phase of competitive advantage in the global Artificial Pancreas Device Systems market.

Key Takeaways from the Artificial Pancreas Device Systems Market Report Study

• Market size analysis for the current Artificial Pancreas Device Systems market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global Artificial Pancreas Device Systems market.
• Various opportunities available for competitors in the Artificial Pancreas Device Systems market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Artificial Pancreas Device Systems market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Artificial Pancreas Device Systems market growth in the future?

Target audience who can benefit from this Artificial Pancreas Device Systems market report study 

• Artificial Pancreas Device Systems product providers
• Research organizations and consulting companies
• Artificial Pancreas Device Systems -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Artificial Pancreas Device Systems  
• Various end-users who want to know more about the Artificial Pancreas Device Systems market and the latest technological developments in the Artificial Pancreas Device Systems market.